[1]张 毅.替格瑞洛对不稳定型心绞痛患者PCI术后缺血事件及炎症因子水平的影响[J].医学信息,2022,35(13):130-132.[doi:10.3969/j.issn.1006-1959.2022.13.030]
　ZHANG Yi.Effect of Ticagrelor on Ischemic Events and Inflammatory Factors in Patients with Unstable Angina Pectoris After PCI[J].Medical Information,2022,35(13):130-132.[doi:10.3969/j.issn.1006-1959.2022.13.030]
点击复制

替格瑞洛对不稳定型心绞痛患者PCI术后缺血事件及炎症因子水平的影响()

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
35卷
期数:
2022年13期
页码:
130-132
栏目:
论著
出版日期:
2022-07-01

文章信息/Info

Title:
Effect of Ticagrelor on Ischemic Events and Inflammatory Factors in Patients with Unstable Angina Pectoris After PCI
文章编号:
1006-1959（2022）13-0130-03
作者:
张 毅
（天津市第四中心医院心血管内科，天津 300140）
Author(s):
ZHANG Yi
(Department of Cardiology,Tianjin Fourth Central Hospital,Tianjin 300140,China)
关键词:
替格瑞洛; 不稳定型心绞痛; PCI术; 缺血事件; 炎症因子
Keywords:
Ticagrelor; Unstable angina pectoris; PCI; Ischemic events; Inflammatory factors
分类号:
R541.4
DOI:
10.3969/j.issn.1006-1959.2022.13.030
文献标志码:
A
摘要:
目的 研究替格瑞洛对不稳定型心绞痛患者PCI术后缺血事件及炎症因子水平的影响。方法 选取2019年8月-2021年5月在我院行PCI术的84例不稳定型心绞痛患者为研究对象，采用随机数字表法分为对照组和观察组，各42例。对照组采用氯吡格雷治疗，观察组给予替格瑞洛治疗，比较两组炎症因子水平、缺血和出血事件发生率、血小板反应指数及不良反应发生情况。结果 两组超敏C反应蛋白（hs-CRP）、白细胞（WBC）、中性粒细胞水平均低于治疗前，且观察组低于对照组，差异有统计学意义（P＜0.05）；观察组缺血事件发生率为7.14%，低于对照组的19.04%，差异有统计学意义（P＜0.05）；观察组出血事件发生率为9.52%，低于对照组的21.43%，差异有统计学意义（P＜0.05）；两组血小板反应指数均低于治疗前，且观察组低于对照组，差异有统计学意义（P＜0.05）；两组不良反应发生率比较，差异无统计学意义（P＞0.05）。结论 替格瑞洛应用于不稳定型心绞痛患者PCI术后效果确切，可预防缺血和出血事件，降低炎症因子水平和血小板反应指数，应用安全性良好。
Abstract:
Objective To study the effect of ticagrelor on ischemic events and inflammatory factors in patients with unstable angina pectoris after PCI.Methods A total of 84 patients with unstable angina pectoris who underwent PCI in our hospital from August 2019 to May 2021 were selected as the research objects. They were divided into control group and observation group by random number table method, with 42 cases in each group. The control group was treated with clopidogrel, and the observation group was treated with ticagrelor. The levels of inflammatory factors, the incidence of ischemia and bleeding events, platelet response index and adverse reactions were compared between the two groups.Results The levels of hs-CRP, WBC and neutrophil in the two groups were lower than those before treatment, and those in the observation group were lower than those in the control group, the difference was statistically significant (P<0.05). The incidence of ischemic events in the observation group was 7.14%, which was lower than 19.04% in the control group, and the difference was statistically significant (P<0.05). The incidence of bleeding events in the observation group was 9.52%, which was lower than 21.43% in the control group, and the difference was statistically significant (P<0.05). The platelet reaction index of the two groups was lower than that before treatment, and the observation group was lower than the control group, the difference was statistically significant (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05).Conclusion Ticagrelor is effective in patients with unstable angina after PCI, which can prevent ischemia and bleeding events, reduce inflammatory factor levels and platelet response index, and has good application safety.

参考文献/References:

[1]毛建斌.瑞舒伐他汀联合替格瑞洛对行经皮冠状动脉介入治疗的冠心病患者的影响[J].实用心脑肺血管病杂志,2017,25(11):93-95.[2]黄晓慧.尼克地尔对经皮冠状动脉介入治疗的不稳定型心绞痛患者心肌的保护作用[J].心脑血管病防治,2018,18(3):238-240.[3]张焕基,陈怡锡,吴智文,等.依折麦布联合瑞舒伐他汀对STEMI患者发生心血管不良事件的影响[J].新医学,2018,49(3):186-189.[4]张晓霞.阿托伐他汀对不稳定型心绞痛并发高脂血症患者血清MMP-9、hs-CRP 等炎症因子及血脂水平的影响[J].中国老年学杂志,2018,38(19):4619-4621.[5]相建民,鲁文庆,赵波,等.琥珀酸美托洛尔联合替格瑞洛治疗不稳定型心绞痛的效果分析[J].解放军预防医学杂志,2019,37(11):45-46.[6]张启杰,鄢高亮,焦慧,等.瑞舒伐他汀辅以替格瑞洛对PCI老年冠心病患者心功能及血脂的影响[J].徐州医科大学学报,2020,40(4):250-254.[7]王赛.氯吡格雷联合阿司匹林对老年冠心病不稳定心绞痛患者血清炎性因子及心功能的影响[J].中国老年学杂志,2018,38(3):529-531.[8]Khera AV,Demler O,Adelman SJ,et al.Cholesterol Efflux Capacity, HDL Particle Number, and Incident Cardiovascular Events. An Analysis from the JUPITER Trial (Justification for the Use of Statins in Prevention:An Intervention Trial Evaluating Rosuvastatin)[J].Circulation,2018,135(25):2494.[9]付明明,陆健.替格瑞洛结合瑞舒伐他汀用于不稳定型心绞痛治疗的疗效分析[J].河北医学,2017,23(6):935-937.[10]黄咏歌.心达康联合阿托伐他汀用于冠心病不稳定型心绞痛的疗效及对血清 NO、ET-1、VEGF 的影响 [J].中国医药科学,2018,8(16):160-163.[11]刘进军,张恒,张宁汝,等.阿托伐他汀联合替格瑞洛治疗冠心病不稳定型心绞痛的疗效观察[J].基因组学与应用生物学,2018,37(3):1002-1008.[12]张海龙.替格瑞洛治疗急性冠状动脉综合征患者的临床研究[J].中国临床药理学杂志,2018,34(6):611-614．[13]刘大渭.替格瑞洛联合阿托伐他汀治疗不稳定型心绞痛的效果观察[J].临床医学,2019,39(5):111-112[14]张艳霞,刘玉清,张娟,等.替格瑞洛与氯吡格雷治疗 冠心病不稳定型心绞痛的疗效[J].深圳中西医结合杂志,2019,29(9):35-36.[15]王义彦,贺朝勇,邓翠.丹参川芎嗪联合阿托伐他汀治疗不稳定心绞痛效果及对血清促炎性细胞因子和血管内皮细胞功能的影响[J].解放军医药杂志,2018,30(5):86-89．[16]李其勇,苏莱,陶剑虹.替格瑞洛对急性心肌梗死患者冠脉血流和短期预后的影响[J].成都医学院学报,2019,14(2):187-192．[17]张欣.负荷剂量替格瑞洛对于急性心梗 PCI 后血清炎性因子、心肌酶与冠脉血流的影响[J].心血管康复医学杂志,2020,29(2):163-167.[18]白娟,闫卫军.负荷剂量替格瑞洛对急性心肌梗死患者介入治疗后冠脉血流、炎症反应及心肌酶谱的影响[J].临床和实验医学杂志,2018,17(7):757-760．

相似文献/References:

[1]刘 华,康美尼,王兴华,等.替格瑞洛对oxLDL诱导的人脐静脉内皮细胞ICAM-1表达的影响[J].医学信息,2018,31(22):81.[doi:10.3969/j.issn.1006-1959.2018.22.022]
　LIU Hua,KANG Mei-ni,WANG Xing-hua,et al.Effect of Ticagrelor on the Expression of ICAM-1 in Human umbilical Vein Endothelial Cells Induced by oxLDL[J].Medical Information,2018,31(13):81.[doi:10.3969/j.issn.1006-1959.2018.22.022]
[2]周忠梅.前列地尔辅助常规治疗冠心病不稳定型心绞痛的效果及对患者凝血功能的影响[J].医学信息,2019,32(20):147.[doi:10.3969/j.issn.1006-1959.2019.20.046]
　ZHOU Zhong-mei.Effect of Alprostadil on Routine Treatment of Unstable Angina Pectoris in Coronary Heart Disease and its Effect on Coagulation Function in Patients[J].Medical Information,2019,32(13):147.[doi:10.3969/j.issn.1006-1959.2019.20.046]
[3]王 焕.替格瑞洛在氯吡格雷抵抗AMI患者PCI术后抗血小板治疗中的应用[J].医学信息,2019,32(24):153.[doi:10.3969/j.issn.1006-1959.2019.24.055]
　WANG Huan.Application of Ticagrelor in the Antiplatelet Therapy of Clopidogrel in Patients with AMI after PCI[J].Medical Information,2019,32(13):153.[doi:10.3969/j.issn.1006-1959.2019.24.055]
[4]杨 晴,郭秋红.血栓前状态分子标志物变化在不稳定型心绞痛合并高血压诊断中的价值[J].医学信息,2020,33(02):172.[doi:10.3969/j.issn.1006-1959.2020.02.055]
　YANG Qing,GUO Qiu-hong.Value of Molecular Marker Changes in Prethrombotic State in the Diagnosis of Unstable Angina Pectoris Complicated with Hypertension[J].Medical Information,2020,33(13):172.[doi:10.3969/j.issn.1006-1959.2020.02.055]
[5]吴浩瑜.院前急救中应用不同抗血小板药物组合对ST段抬高型急性心肌梗死患者近期心血管事件的影响[J].医学信息,2021,34(22):57.[doi:10.3969/j.issn.1006-1959.2021.22.016]
　WU Hao-yu.Effects of Different Antiplatelet Drug Combinations in Pre-hospital Emergency Treatment on Recent Cardiovascular Events in Patients with ST-segment Elevation Acute Myocardial Infarction[J].Medical Information,2021,34(13):57.[doi:10.3969/j.issn.1006-1959.2021.22.016]
[6]程 林.替格瑞洛对冠心病患者PCI治疗术后冠脉微循环功能的影响[J].医学信息,2020,33(07):156.[doi:10.3969/j.issn.1006-1959.2020.07.051]
　CHENG Lin.Effect of Ticagrelor on Coronary Microcirculation Function in Patients with Coronary Heart Disease After PCI Treatment[J].Medical Information,2020,33(13):156.[doi:10.3969/j.issn.1006-1959.2020.07.051]
[7]程 林.低剂量替格瑞洛治疗稳定型冠心病患者的疗效及安全性评价[J].医学信息,2020,33(08):161.[doi:10.3969/j.issn.1006-1959.2020.08.053]
　CHENG Lin.Efficacy and Safety of Low-dose Ticagrelor in the Treatment of Stable Coronary Heart Disease[J].Medical Information,2020,33(13):161.[doi:10.3969/j.issn.1006-1959.2020.08.053]
[8]潘小玉,张再伟,李 虎.吲哚布芬治疗不稳定型心绞痛的有效性和安全性的Meta分析[J].医学信息,2020,33(14):80.[doi:10.3969/j.issn.1006-1959.2020.14.023]
　PAN Xiao-yu,ZHANG Zai-wei,LI Hu.Meta Analysis of the Efficacy and Safety of Indobufen in the Treatment of Unstable Angina[J].Medical Information,2020,33(13):80.[doi:10.3969/j.issn.1006-1959.2020.14.023]
[9]王亚飞.振源胶囊辅助治疗不稳定型心绞痛的临床疗效及对血NT-proBNP、HCY水平的影响[J].医学信息,2022,35(21):88.[doi:10.3969/j.issn.1006-1959.2022.21.020]
　WANG Ya-fei.Clinical Efficacy of Zhenyuan Capsule in Adjuvant Treatment of Unstable Angina Pectoris and its Effect on Blood NT-proBNP and HCY Levels[J].Medical Information,2022,35(13):88.[doi:10.3969/j.issn.1006-1959.2022.21.020]
[10]杨岸霖.不稳定型心绞痛的发病机制及药物研究[J].医学信息,2022,35(01):70.[doi:10.3969/j.issn.1006-1959.2022.01.017]
　YANG An-lin.The Pathogenesis and Drug Research of Unstable Angina Pectoris[J].Medical Information,2022,35(13):70.[doi:10.3969/j.issn.1006-1959.2022.01.017]

更新日期/Last Update: 1900-01-01